Leuprorelin acetate hormone therapy in the management of ovarian endometriosis: A case report
Leuprorelin acetate hormone therapy reduced ovarian endometriosis mass size and patient pain, demonstrating its potential as a non-surgical management option.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
This case report evaluated leuprorelin acetate hormone therapy for a 37-year-old woman diagnosed with ovarian endometriosis at an obstetrics and gynecology polyclinic, using interviews, observation, physical exams, medical records, and diagnostic documentation, with narrative analysis alongside concurrent data collection. Leuprorelin acetate was administered as 3.75 mg injections for three months, during which ultrasound showed reduction in the size of the ovarian mass and the patient’s pain decreased significantly. The paper’s limitation is that it is based on a single patient case without a comparison group. This paper is centrally about endometriosis — specifically ovarian endometriosis managed with leuprorelin acetate hormone therapy.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Abstract
Full text
6,604 characters
· extracted from
oa-doi-fallback
· 5 sections
· click to expand
Background
Method
Results
Conclusion
References
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (15)
- Abdominal wall endometriosis (a narrative review) via openalex
- A Case Report of A Larg Rectus Muscle Size Endometriosis via openalex
- Clinical Diagnosis and Early Medical Management for Endometriosis: Consensus from Asian Expert Group via openalex
- Efficacy of Laparoscopic Surgery Combined With Leuprorelin in the Treatment of Endometriosis Associated With Infertility and Analysis of Influencing Factors for Recurrence via openalex
- Endometriosis and Medical Therapy: From Progestogens to Progesterone Resistance to GnRH Antagonists: A Review via openalex
- GnRH agonists in the treatment of symptomatic endometriosis: a review via openalex
- Leuprorelin acetate hormone therapy in the management of ovarian endometriosis: A case report via openalex
- Novel pharmacological therapies for the treatment of endometriosis via openalex
- Oral GnRH Antagonists in Combination with Estradiol and Norethindrone Acetate for Pain Relief Associated with Endometriosis: A Review of Evidence of a Novel Class of Hormonal Agents via openalex
- Oral Gonadotropin-Releasing Hormone Antagonists in the Treatment of Endometriosis: Advances in Research via openalex
- Pemilihan Terapi Konservatif dan Operatif pada Endometriosis via openalex
- Pharmacokinetic considerations for gonadotropin-releasing hormone agonists and antagonists to treat endometriosis via openalex
- Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose–response manner: a randomized, double-blind, placebo-controlled study via openalex
- W4390637331 via openalex
- W4214713448 via openalex
Cited by (2)
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00